Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples